BACKGROUND The role of human papillomavirus (HPV) in the induction and maintenance of cervical, anogenital, and some oropharyngeal carcinomas is well recognized, but its role in cutaneous squamous cell carcinoma (SCC) remains to be elucidated. HPV is thought to act as a possible cocarcinogen in the development of SCC.
N onmelanoma skin cancer (NMSC) is more common than lung, breast, prostate, and colon cancers combined, and its rate in increasing 4-8% yearly. 1 Although the majority of NMSC can be treated surgically, these cancers are associated with high morbidity and represent a significant burden on the healthcare system. Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common types of NMSC. BCC is four times as common as SCC in fair-skinned individuals, although SCC is more prevalent in darker skin types. SCC is the second most common type of NMSC after BCC. 2 Major risk factors for the development of SCC are ultraviolet radiation (UVR) exposure, fair skin, and immunosuppression. 3 In addition to sun exposure, the clinical behavior and epidemiology of SCC suggest a viral etiology. 4 Organ transplant recipients (OTRs) have a risk of SCC 65-100 times as great as that of the general population, [4] [5] [6] [7] an incidence ratio similar to other viral cancers, including human herpes virus-8 (HHV-8)-mediated Kaposi's sarcoma. 8 The keratoacanthoma subtype of SCC is able to regress spontaneously and may represent a midpoint between a viral wart and invasive SCC. 9 There are a variety of mechanisms by which oncoviruses lead to cancer (Table 1 ; reviewed by Arron 10 ). Small DNA viruses and integrated retroviruses can express viral oncogenes that target cellular tumor suppressor genes directly and disrupt normal cell cycle controls, leading to transformation. Nontransforming retroviruses may integrate near cellular oncogenes, disrupting expression (somatic mutagenesis). Finally, some viruses trigger cancer by stimulating chronic inflammation, leading to carcinogenesis.
Well-known examples of viral-associated NMSC include HHV-8-associated Kaposi's sarcoma and Merkel cell polyomavirus-associated Merkel cell carcinoma, both caused by DNA oncoviruses.
The search for a viral etiologic agent in SCC has focused on the human papillomavirus (HPV). This virus is an attractive candidate given its etiologic role in verruca vulgaris, condyloma acuminata and anogenital and some head and neck SCCs. b-genus HPV is also associated with cutaneous SCC in the genodermatosis epidermodysplasia verruciformis (EDV). 11 The association between alpha (a) HPV types and cervical cancer has been well established. Persistent infection with a high-risk a HPV type is necessary, although not sufficient, for the development of cervical cancer, 12 and almost all cervical cancers test positive for HPV DNA. 12 Infection with high-risk HPVs (16, 18, 31, 33, 45) , whether clinically evident or not, is the major risk factor for the development of cervical cancer. 13 In addition, the attributable risk of HPV for cervical cancer is higher than the risk associated with smoking for lung cancer and hepatitis B for liver cancer. 12, 14 Certain environmental factors such as smoking; use of oral contraceptive pills; coinfection with the human immunodeficiency virus (HIV), herpes simplex virus, or chlamydia trachomatis; immunosuppression; and lack of male circumcision can further increase this risk. 12, 14, 15 Molecular studies have shown that HPV E6 and E7 proteins deregulate important controls in the cell cycle by interacting with p53 and Rb, respectively. 16 As a consequence, HPV-infected host cells acquire defects in differentiation and apoptosis, leading to immortality and malignant potential. 17 Based on this evidence, various groups have sought to examine the association between HPV and cutaneous SCC, but before cancer causality can be attributed to a viral agent, epidemiologic evidence and a plausible biologic mechanism for oncogenesis must exist. The objective of this review is to update the reader on the epidemiologic association between HPV and SCC. To give the reader a framework with which to understand the field, we will briefly review relevant HPV biology and the array of sampling and detection techniques used in these studies. Finally, the clinical implications of an association between HPV and SCC will be discussed. 
Human Papillomavirus
Papillomaviridae is a diverse family of nonenveloped DNA viruses that are highly host specific. They infect humans, other mammals, birds, and reptile species. Papillomaviridae replicate exclusively in keratinocytes and depend on keratinocyte differentiation to complete their life cycle. 18 HPV presumably gains entry through microabrasions of the skin or mucosal surface, initially infecting follicular 19 or eccrine stem cells. 20 After initial entry, interactions between viral capsid proteins and cell surface glycosaminoglycans and proteoglycans (e.g., heparan sulfate) allow viral attachment ( Figure 1 ). [21] [22] [23] Specific receptor interactions and endosomal transport aid in viral entry into the cell. The virus then disrupts the endosome, and the viral genome is granted access to the cell nucleus, where it replicates. Once in the nucleus, HPV DNA exists in an episome separate from the host DNA, although high-risk (carcinogenic) HPV types can integrate into the host genome. 24 The 8-kb viral genome is composed of genes expressed late (L) and early (E) in the life cycle. The L1 protein is the major capsid protein and is relatively well conserved between HPV types. It is the basis of prophylactic vaccines and is used for classification and phylogenetic analysis. 25 In specific high-risk types of HPV such as 16 and 18, proteins E6 and E7 immortalize the cell, preventing apoptosis and allowing the continuous replication of viral DNA. E6 is a multifunctional protein that binds and mediates the degradation of the tumor suppressor Cervical stratified squamous epithelial cell architecture and the expression of human papillomavirus (HPV) proteins after infection. Daughter cells of epithelial stem cells divide along the basement membrane and then mature vertically through the epithelium without further division (right side). After introduction of HPV into stem cells in the basal layer of the epithelium, expression of viral nonstructural proteins occurs. Under the regulation of these proteins, the dividing cell population expands vertically, and epithelial cell differentiation is delayed and is less complete. Viral proteins are expressed sequentially with differentiation as shown, and mature virions are produced only in the most superficial layers of the epithelium. Intraepithelial antigen-presenting cells (APCs) are depleted in the HPV infected epithelium. Reproduced with permission from Frazer. 21 gene p53. 26 It also binds other cellular proteins, affecting cellular metabolism and driving the cell to immortality. E7 activates telomerase and inactivates retinoblastoma protein, preventing cell cycle inhibition. 26, 27 More than 100 HPV types have been characterized, with approximately 90% being encompassed by the alpha (a), beta (b), and gamma (c) genera ( Figure 2 ). 25, 28 Classification is accomplished using DNA sequence identity in the L1 capsid region, which can range from 40% for divergent genomes to more than 99% for closely related isolates. HPV in the same genus share at least 60% identity, and types share 76-89% identity. 25 Specific types have specific tropism, with the a genus primarily infecting mucosal epithelium and the b, c, mu (l), and nu (m) genera infecting cutaneous epithelium. The b genus, which includes HPV 5 and 8, encompasses those types known as epidermodysplasia verruciformis (EV) types because of the association of these types with that genodermatosis. 29
Although the significance of specific types of HPV is well recognized in cervical and anogenital SCC, as well as a subset of oropharyngeal SCC, its etiologic role in cutaneous oncogenesis is debated.
Immunity and HPV
The adaptive immune response to HPV is antibody and cell mediated, although the humoral response to natural HPV infection is weak. 30, 31 There is clinical evidence that a functional T-cell response remains a Figure 2 . Phylogenetic tree inferred from the L1 nucleotide sequences of 189 papillomaviruses. Reproduced with permission from Bernard and colleagues. 25 C U T A N E O U S S C C A N D H P V major mechanism of immunity against HPV. For example, the presence of a robust T-cell and macrophage infiltrate correlates with regression in genital warts. 32 Patients who have genetic immune defects in the quantity or quality of their T-cell repertoire often have susceptibility to viral infections as a distinct feature of their genetic disease. [33] [34] [35] Patients who have Dock8 deficiency or idiopathic T-cell lymphocytopenia can have extensive cutaneous verrucae. The degree of risk that these patients have of developing SCC is not clear, although SCC have been reported in these patients. 36 Neither is it known whether the predisposition to developing SCC is directly related to an inability to mount an appropriate defense against HPV or if it is a nonspecific consequence of the underlying immune defect. Finally, patients who have an acquired or iatrogenic cellular immune defect, such as those with HIV and those who have undergone solid organ transplantation, have inefficient cell-based immunity to HPV. HIV infection reduces the likelihood of HPV clearance, 37, 38 and OTRs can have a variety of cutaneous viral infections, the most common of which is warts 39, 40 ; 50% of renal transplant patients with 5-year graft survival have warts. The consequence of iatrogenic immunosuppression and the inability to clear viral infections can be far reaching, because solid organ transplantation increases the risk of other viral-associated malignancies. 41 Although this is presumed to be from the host's inadequate control of viral infection, the exact mechanism of tumor initiation and progression is poorly understood. Given the high incidence of cutaneous SCC in OTRs, identifying a clear link between HPV and SCC would have important implications for therapy and prevention. 31 
Ultraviolet Light and HPV
The relationship between of ultraviolet (UV) light, HPV infection, and HPV-related carcinogenesis is not fully understood. In a case-control study of cutaneous SCC in a Dutch population, a history of painful sunburn episodes was associated with recovery of EV-HPV DNA from plucked eyebrow hairs, 42 although greater lifetime sun exposure in the same cohort was associated with the opposite result. One reasonable hypothesis is that local immunosuppression by UV light promotes HPV infection. 42 UV light is known to suppress local cell-mediated immunity and can impede antigen presentation by depleting the Langerhans cells and interfering with antigen presentation. 43 UV light also attenuates the effector memory response. 44 Given the dependence of the body's defense mechanism against HPV on an intact T-cell response, it is reasonable to infer that UV light promotes HPV infection through cutaneous immunosuppression. The destructive effects of UV light may also play a role in HPV infection. Salem and colleagues demonstrated recovery of more HPV in psoriatic plaques treated with UVB and psoralen plus UVA (PUVA) than in nonirradiated psoriatic plaques and normal controls. 45 That same study found that there was an even greater recovery in PUVA-treated patients with psoriasis than in those treated with narrowband UVB (NB-UVB), suggesting that the UV wavelength and degree of damage is important in HPV infection. Furthermore, when the authors examined UV-treated patients with vitiligo, they found that HPV recovery in lesional skin in these patients was similar to that in the psoriasis-PUVA group but significantly higher than in the psoriasis-NB-UVB group. This contradicts the concept that psoriatic skin is more permissive than normal skin tothe viral presence 46 and strengthens the argument that UV treatment may facilitate HPV infection.
Detection Methods
Studies assessing the association between HPV (mainly the b types) and SCC have varied greatly in their methods of viral detection. Detection of HPV in the skin requires a sampling strategy and a measurement method for viral nucleic acid, protein, or serum antibody response.
Sample Collection
The first step in assessing the presence of HPV is acquiring an adequate sample ( Table 2 ). Skin biopsy is considered the criterion standard in sampling for HPV testing. Skin biopsies can yield information about HPV in layers deep to the stratum corneum, which may reveal virus in the stem cell of the hair follicle or the eccrine ducts. 19, 20 Nonetheless, it is not known whether HPV DNA detection from healthy skin represents viral particles or superficial or deep viral infection. Some have advocated tape stripping biopsy sites to reduce surface contamination because the virus is shed from the skin, and this significantly reduces the detection of HPV DNA. 47 Biopsy is a minimally invasive procedure but requires performer skill and moderate cost, which may make it impractical for large cohort studies. Skin swabs are a more convenient sampling method, allowing for quick, noninvasive, painless sampling that can be repeated multiple times with little risk. The disadvantage is that it is difficult to determine whether a positive sample represents contamination, carriage, or transient or persistent infection. Presumably, multiple positive samples of the same HPV type over a period of time would be more likely to be because of persistent infection. Plucked hairs represent another tissue specimen that may be tested for HPV, because hair follicles are a reservoir for latent b-HPV. 7 This sampling method should have a lower risk of surface contamination than skin swabs. 48 Hair pluck is noninvasive, has little risk, and can be performed multiple times. These less-invasive methods, although more feasible, may not be as clinically relevant as biopsy. Finally, blood samples can be used to identify serum antibodies to specific HPV types. Drawing blood is simple and quick and can be repeated multiple times, but information gathered is limited to serology.
Viral DNA Detection
Detection of HPV is frequently based on molecular assays for viral nucleic acid (Table 3 ). Most studies use polymerase chain reaction (PCR) amplification with degenerate or multiplexed primers to amplify a broad range of viral types. Many published primer sets target the L1 capsid gene, because this is the most conserved area. Specific genotyping of amplified material is then performed with sequencing, blot, or bead-based readout. [49] [50] [51] [52] [53] [54] [55] [56] Microarray detection of HPV has been used for readout of similarly amplified PCR products, 57-65 although comprehensive 
Serology
The serologic response to different viral proteins is usually tested using enzyme linked immunosorbent assay (ELISA). Current ELISA techniques make use of virus-like particles (VLPs), which are noninfectious aggregates of capsid protein produced in the laboratory and do not contain viral DNA. Serologic responses are usually measured against the L1 or E6 proteins (Table 3 ). Some epidemiologic studies use serologic testing because most HPV infections are rapidly cleared, and serology detects current infection and prior viral exposure. In contrast, DNA detection methods are limited to a specific body site and indicate only current infection. 67 Serology provides a useful epidemiologic tool to investigate the variety of HPV types and their distribution within the community, but for cutaneous HPV infections, seroconversion may not appear until months after-wards. 68 Not all hosts mount an antibody response to HPV, and cross-reactive antibodies between different HPV types may complicate the picture. 69, 70 Although not sufficient to prove causality, serology may be used as a complement to other detection methods or to examine a population longitudinally.
HPV Carriage in Healthy Individuals
HPV is ubiquitous on the skin and has been detected in newborns, young children, and adults. 71 With increasing age, more HPV types are isolated, and seroreactivity to more types is seen. 71 HPV persistence with the same types is common, and family members often share the same types. 48, 72 Different studies using different sampling techniques (swab, hair pluck, serology; Table 4 ) have shown that HPV types 5, 8, and 23 are most commonly detected, and persistence of the same HPV type is frequently seen. 48, 71, [73] [74] [75] [76] [77] Different ethnicities may harbor different HPV types. 78 The most prevalent type and the only type common to all countries studied (Japan, There was no difference in the prevalence or spectrum of HPV types found in sun-exposed and non-sun-exposed normal skin. Significant association between NMSC and presence of EV HPV DNA in normal skin
Bangladesh, Ethiopia, Zambia, Sweden) was HPV 5 (overall prevalence of 6.5%).
Studies Using Skin Swab
A small study (n = 16) of newborns and young children showed that 45% of newborns who underwent forehead skin swabs had HPV DNA in the first few days of life, and some shared the same types with their mothers. 71 By 4 years, HPV was detected in 70% of children. 71 Family members may share some of the same HPV types. 79 Another study arguing for intrafamilial transmission showed that the vast majority of HPV types in children are also found in one or both parents. 48 One-third of HPV types that persisted in parents also persisted in their children, although no specific type predominated. Type-specific persistence was generally more common in adults (92%) than children (66%). 48 The same HPV types have been isolated from 48% of healthy adults after a period of 6 years, indicating chronic persistence. 72 Persistence has not been significantly associated with age, sex, history of warts, or HPV genus. 72 Viral transmission, although not systematically studied, conceivably occurs through direct contact with skin or its remnants. 80 A great multiplicity in HPV genotypes has been observed in healthy, nonimmunosuppressed adults, with positivity ranging from 42% to 87%. 48, 49, 72, 78, 79, [81] [82] [83] [84] Some studies have investigated different HPV profiles in different ethnicities and climates. 78 HPV DNA prevalence is lower in Zambian samples than in those from Sweden (p < 0.01) and Bangladesh (p < 0.05). 78 HPV 5 was the only type found in samples from all five countries (Bangladesh, Japan, Ethiopia, Zambia, and Sweden) studied. 78 Sun exposure, 83 history of skin cancer, 83 and older age 81, 82 have been found to be risk factors for HPV detection. One study using serial sampling in 40 adults and children (484 total samples) showed that HPV positivity was on average higher in samples from the forehead (79%) and back of the hand 
(81%) than buttocks (64%), implicating UV radiation as a possible risk factor, although environmental exposure unrelated to sun is also a possibility. 48 
Studies Using Hair Pluck
A high rate of detection of various HPV types has been found in hair-pluck samples from healthy individual, with certain types predominating. Earlier studies may show a lower rate, but that may be due to less-sensitive detection methods. 85 Detection ranges from 84% to 91% in larger studies, and HPV 23 is the most commonly detected. 74, 86, 87 This may indicate that HPV 23 has a greater propensity to infect or maintain infection in the follicle than other types, although HPV 23 DNA in hair follicles has not been shown to be significantly associated with seropositivity, whereas other HPV types have. 74 Thus, HPV 23 may cause only transient infection or have the ability to evade the host immune system. HPV 24 and HPV 36 have also been reported to be common. 74, 86 β-HPV detection increases over time and is associated with age, but not with sex, skin type, sunburn, or sun exposure. 86, 87 Studies Using Serology Serologic analysis allows for larger-scale studies, allows a population to be tracked over time, analyzes trends in HPV infection, and complements other detection methods. A cross-sectional study from Germany examined the prevalence of the L1 (major capsid protein) antibody given 29 cutaneous and five mucosal HPV types from all five genera (a, b, c, l, m) in 1,797 sera from the general population. 67 The overall seroprevalence for any of the 34 HPV types was approximately 60%, but the type specificity depended on sex and age. For all types and both sexes, antibody reactivity was lowest in children. 67 Antibodies to the high-risk HPV 16 were higher after puberty in women but not in men. 67 Antibodies to HPV 8 increased with age, with prevalence peaks at aged 40 and 60 in women and 50 and 70 in men. 67 A London-based study of 928 subjects observed statistically significant differ-ences between Caucasians and non-Caucasians, with higher β-HPV 93 in non-Caucasians and higher l-HPV 1 and HPV 4 in Caucasians. 88 This association held for immunocompetent and immunosuppressed subjects. No HPV seroprevalence difference was observed according to immune status. 88 Sun exposure risk has also been assessed by examining populations from different geographic latitudes. Overall HPV prevalence (β-HPV types 50-57%, β-HPV types 40-48%) and the most frequent β-HPV (HPV 8 followed by 15, 17, 38 and 49) and β-HPV (HPV 4 and 65) were similar in healthy individuals living in the Netherlands, Italy, and Australia. 89 These results are consistent with those of other studies examining β-HPV types that have found HPV 8, 15, and 38 to be the most prevalent in healthy controls. 73, 77 This may indicate that the distribution of β-HPV types is similar in those of European ancestry and may be less attributable to sun exposure. An even higher rate of HPV seropositivity was found in 411 patients undergoing skin cancer screening in Florida (91.2% were positive to 1 cutaneous HPV types and 78.8% to 2 types). 90 Antibodies to the L1 (the major capsid protein) and E6 viral proteins (a nonstructural intracellular protein) are rarely found concomitantly. 91 Is HPV Involved in the Development of SCC in Immunocompetent Individuals?
Tissue Evidence Indicating a Positive Correlation Between HPV Detection in SCC
Numerous studies have examined the presence of HPV in NMSC, premalignant and benign lesions, as well as normal, uninvolved skin ( Table 3) . Some of these studies do not distinguish SCC from actinic keratoses (AKd), Bowen's disease, or BCC. Others assess "tumors" or NMSC rather than SCC specifically. The inclusion of non-SCC tumors may mask or give a false association with HPV. Thus, for future studies, the different NMSC subtypes should be separated.
Multiple studies have indicated a relationship between SCC and various HPV types in immunocompetent patients. 73, 81, 83, [92] [93] [94] [95] [96] [97] [98] When skin lesions and control skin were tape stripped (N = 349), SCC and benign lesions were more often positive for HPV DNA than healthy skin samples 93 ; HPV 1 was more common in benign lesions (odds ratio (OR) = 3.47), and HPV 2 was more common in SCC than benign lesions (OR = 4.40). 93 In general, HPV DNA was more associated with sun exposure (OR = 4.28) in lesions and healthy skin. 93 Localized immunosuppression from UV light may thus be contributing to higher HPV loads. Other studies that have detected higher HPV 2 in SCC (OR = 4.0) did not find a link with sun exposure. 92 Some studies have shown that the history of NMSC has been correlated with higher HPV detection in normal skin (OR = 6.41), but higher HPV detection was not correlated with sun exposure. 94 To complement skin biopsy, Andersson examined serum samples from the same immunocompetent individuals (N = 434). 73 SCCs had more HPV DNA than BCCs and AKs than benign lesions (OR = 2.08). 73 Nonetheless, seroreactivity to HPV was similar between the groups, the only significant difference being higher in patients with SCC than in those with BCC. 73 Although most positive associations between SCC and HPV have been of the cutaneous b types, high-risk mucosal types have been implicated in some reports. 96, 97, 99 Zheng and colleagues found that a higher percentage of extragenital Bowen's disease was positive for HPV DNA than control skin, with mucosal types detected in higher amounts using semiquantitative PCR. 97 Other studies have shown that HPV detection was the same in extragenital Bowen's disease in non-and sun-exposed skin. 99 Skin swabs from immunocompetent individuals have detected more HPV DNA in those who have spent more time outdoors, those with a history of NMSC, and those who actively have AK or SCC. 81, 83 In the Netherlands, presence of b-HPV in plucked eyebrow hairs was associated with a three times greater risk of SCC, although this was not the case in Australia or Italy. 74 
Tissue Evidence Indicating a Lack of Correlation Between HPV Detection in SCC
Just as an abundant amount of data suggests a link between HPV and SCC, a great body of evidence suggests otherwise. 49, 84, 92, 93, [100] [101] [102] [103] [104] [105] Although some studies do not find a significant difference in HPV detection rates, others note a predilection of certain HPV types for SCC. 84, 92, 93, 101, 102 Newer studies examining viral messenger RNA levels, which correlate with viral activity, have not supported a transcriptional mechanism to link HPV with SCC. 106 The first study using tape stripping of tumors found less HPV positivity in all samples (benign, premalignant, BCC, and SCC), although SCCs were not significantly more positive than other tumors. 47 Some studies have found HPV to be more common in AK than SCC, BCC, benign lesions, or normal skin. 84, 102, 104, 105 Because HPV 2 had been previously linked to SCC but not benign lesions (see above), Vasiljevic and colleagues examined four HPV types of species two using real-time PCR in SCC, BCC, seborrheic keratoses, AK, and normal skin. The members of HPV species two were preferentially found in AK, albeit in low copy numbers. 104 Before this study, Weissenborn and colleagues also examined HPV using real-time PCR and detected a higher load in AK. 105 HPV 5 and 8 (oncogenic types) and HPV 38 have also been implicated in AK. 84, 102 Although oncoviruses are usually detected in the corresponding tumor tissue, some have argued that HPV may be involved in the early steps of oncogenesis but not in tumor maintenance, explaining its presence in premalignant lesions. If this were the case, then an explanation for tumoral loss of HPV infection after malignant degeneration is needed. Additionally, the studies that have examined AK and SCC did not take into account sun exposure, which may have been the reason for higher HPV detection in AK. In turn, C U T A N E O U S S C C A N D H P V HPV may not be involved in cutaneous oncogenesis but may be more adept at infecting normal or premalignant cells than cancerous cells.
Two studies (N = 85 and N = 82, SCC) using lesional, perilesional, and healthy skin biopsies from the same patient or other individuals did not show any difference in overall HPV DNA between SCC, benign lesions, and healthy skin, although as indicated above, these studies found HPV species two to be more common in SCC. 92, 93 Another large study (101 SCC, 101 BCC) did not find any difference in HPV detection between SCC and BCC but found SCC to be more often infected with HPV genus β-species 1 (including type 5 and 8), multiple HPV types, and certain HPV types reported to be important in skin cancer (5, 8, 15, 20, 24, 36, 38) . 101 Two smaller studies did not find any difference in HPV detection between SCC and BCC either, 100, 103 although these studies did not examine normal skin controls. 100, 101, 103 Although previous studies have examined HPV DNA levels, messenger RNA transcriptome sequencing has recently been used to assess β-HPV gene expression in SCC from immunocompetent and immunosuppressed individuals. Sequencing did not identify β-HPV expression in any of the SCCs studied. 106 Although 30% of SCC tumors and 28% of normal skin samples contained HPV DNA according to nested PCR, the viral load was found to be extremely low, with most tumors having fewer than 1 HPV copies per cell. 106 Although the previously described studies examined skin biopsies, a few have examined eyebrow hair. Two studies (n = 64 SCC, n = 25 SCC) that examined plucked eyebrow hair in individuals with SCC did not find a significantly greater association with HPV DNA than with normal skin, BCC, or AK. 91, 107 
Serologic Evidence
Several large studies and some smaller ones have examined the association between SCC and serum antibodies against HPV (Table 5 ). Most studies have found a positive relationship between antibody response to HPV (whether against a single or specific type or multiple types) and SCC development, 74, 77, 91, [108] [109] [110] with only one study failing to find any correlation. 73 The two largest serology-based studies found a positive correlation. An international, multicenter, epidemiologic study (689 SCC cases, 845 controls) showed that a positive antibody response to four or more β-HPV types was associated with SCC (OR = 1.8), especially in fair-skinned individuals. 74 Antibodies against certain types correlated with eyebrow HPV presence. 74 These may indicate that some HPV types cause only transient infection or may avoid detection by the host's immune system. In the other large study (663 SCC cases, 898 BCC cases, 805 controls), Karagas and colleagues found a correlation with an antibody response against HPV and SCC but not BCC, with the OR for SCC increasing with increasing number of β-HPV types. 111 These findings confirm the results of an earlier study by the same group (252 SCC cases, 525 BCC cases, 461 controls) that detected HPV antibodies more frequently in individuals with SCC (OR = 1.6) than in controls; multiple β-HPV antibodies further increased that risk. 77 Seropositivity to β-HPV types 5, 77 8, 91, 108, 110, 112 15 , 109 17, 109 20, 112 and 38 109, 112 and c HPV 50 109 has been associated with SCC development. In 107 patients, HPV seropositivity at baseline was associated with risk of developing a second SCC after 5 years for a number of b and c types and one m type (HPV 5, 9, 15, 17, 23, 24, 41, 76) . 113 One study found a negative correlation between HPV 15 serology and SCC. 110 Individuals with SCCs on chronically sun-exposed sites were more likely to have antibodies to β-HPV types than those with SCCs on sun-protected sites. 77 In an interesting, albeit small study, HPV L1 protein seroreactivity was shown to increase and E6 seroreactivity to decrease with the severity of the skin lesion (control, AK, SCC). The authors speculated that individuals with SCC may not have the ability to mount a response to HPV E6 proteins or that antibodies to E6 may be protective. 91 Antibodies to β-HPV have been detected close to or at the time of SCC occurrence but not before and more frequently in those with SCC of sun-exposed sites. 77 Seropositivity to HPV 8 viral-like particles has been associated with the development of AKs. 114 Not all serologic studies have found a positive correlation with HPV and SCC. Andersson and colleagues examined both tissue and serum samples and reported that seroprevalence was the same for patients with SCC versus controls but higher in SCC patients versus BCC patients. 73 The presence of HPV DNA in tissue and antibodies to the same HPV type in the serum were not significantly correlated, but seropositivity to any HPV type was more common among those positive for cutaneous HPV DNA of any type. Plasmeijer et al. followed a cohort of 1,311 participants who had serologic testing for β-HPV types from 1992 to 2007 for the development of new SCC (n = 150). No correlation was found between HPV serology and the later development of SCC, even with stratification according sex, skin color, and sunburn propensity, although when a sample subset (cases collected in 1992) was stratified, the risk of SCC was two times as great in HPV serologically positive individuals. 115 
HPV Carriage and Immunosuppression
As with immunocompetent individuals, HPV carriage is common in immunosuppressed individuals, with HPV 5, 20, 23, and 24 being most prevalent. 72, 75, 82, 86 In a large (N = 351) biopsy-based study, HPV positivity was evident in one-third of normal skin samples from renal transplant recipients (RTRs). 116 Harwood and colleagues examined normal skin samples from both sun-exposed and nonsun-exposed sites in 39 immunocompetent individuals and 38 RTRs and found a HPV prevalence of 86% in RTRs, twice as much as in their immunocompetent counterparts. 94 Sun exposure, duration of transplantation, age, sex, and history of NMSC did not alter risk of presence of HPV, 94 but after adjusting for history or presence of NMSC, β-HPV types were more common on the skin of RTRs (OR = 21); mixed infections with different HPV types were also more common. 94 In contrast to that study, 94 a case-control study from Germany showed that HPV prevalence from benign lesions and normal skin was similar in transplant and non-transplant groups. 117 Another study analyzing benign keratotic lesions in RTRs with and without a history of skin cancer found similar prevalence rates (55% and 53%, respectively). 118 A large variety of β-HPV types were seen, with greater prevalence in sun-exposed areas of those with a history of skin cancer. 118 Antonsson and colleagues examined skin swabs from RTRs, individuals undergoing dialysis, and healthy controls and found that RTRs were more likely to be HPV positive than the other two groups (Table 4) , 82 and approximately 12% of the RTRs had a history of skin cancer, whereas no skin cancer was reported in the other groups. HPV DNA was also more prevalent on the forehead than at other sample sites, 82 consistent with other studies indicating greater HPV detection in sun-exposed areas. Others have found similar initial HPV rates in (69%) and RTRs (71%) but higher rates of persistence in RTRs (90%) than immunocompetent individuals (71%) 6 years later. 72 Most persistent infections were β-HPV types, with HPV 20 predominating. 72 A few studies have examined HPV DNA in plucked hairs from immunosuppressed individuals. 86, 116 The largest of these examined 560 OTRs from five European centers and found HPV detection prevalence of 81% to 98% and that HPV 23 was the first or second most common type. 86 HPV 24, 36, and 38 were also highly prevalent. The results were similar to those of immunocompetent individuals. 86 As indicated earlier, this may indicate greater HPV 23 maintenance of infection in the hair follicle than with other HPV types. Another hair pluck study specifically examining HPV 5, a high-risk type associated with EDV, found a higher rate of detection in RTRs, although there were no differences in samples from individuals with and without skin cancer in either C U T A N E O U S S C C A N D H P V group. 75 For the most part, seroprevalence in this population is similar to that in immunocompetent individuals, with the only difference being that reactivity to HPV 8 is greater in immunosuppressed individuals. 88, 119, 120 Antibodies against HPV 8 (high-risk EV type) viral particles have been found to be significantly higher (p < 0.001) in RTRs regardless of history of skin cancer (21.1% vs 7.6% controls). 121 Several studies have examined antibodies to HPV in immunosuppressed individuals without history of skin cancer, including two large UK-based studies. 88, 119 These studies indicated no difference in seroprevalence between immunocompetent and immunosuppressed individuals. 88 Seroprevalence to at least one HPV type in OTRs varied from 86% to 90%. 88, 119 Seropositivity to high-risk mucosal types was higher in women, younger patients, and non-Caucasians. 88, 119 Immunocompetent individuals with a history of NMSC also had higher seroreactivity (45%) than healthy controls. 121 Is HPV Involved in the Development of SCC in Immunosuppressed Individuals?
The evidence implicating HPV in the pathogenesis of NMSC in immunosuppressed individuals is mixed ( Table 5 ). Several studies have linked HPV with SCC, but many studies have been small and others uncontrolled. Newer studies have shown low transcriptional activity of the virus. Thus, even though HPV DNA has been detected in prior studies, the low rate of DNA transcription may indicate that HPV is not involved in cutaneous oncogenesis.
The largest of these studies (210 SCC cases, 394 controls) showed that individuals with b-HPV DNA (from hair pluck samples) and antibodies against the same type (concordant DNA and antibodies) were at significantly greater risk of SCC, even if each measure did not independently show an association. 122 Biopsy-based studies comparing lesions from OTRs with those from nonimmunosuppressed individuals detected more HPV in SCC from OTRs but not BCC, warts, or premalignant lesions. 117, 123 These studies have shown HPV 5 and 8 to be more frequent in SCC of OTRs. 117, 123 Another study (N = 148) revealed a difference in HPV detection in SCC (84% vs 27%), BCC (75% vs 36%), and premalignant lesions (88% vs 54%) between the two groups. 124 This result is consistent with earlier, smaller studies, 103, 120 although one could argue that this finding may simply be the result of a higher viral load in immunosuppressed individuals and does not necessarily indicate a role for HPV in cutaneous oncogenesis. This could be controlled for by assessing uninvolved skin from OTRs with and without a history of skin cancer and OTR SCC lesions.
Longitudinal studies of viral load and number of types in OTRs and the subsequent development of SCC would also be helpful.
Uncontrolled studies have indicated high rates of HPV detection in premalignant lesions and SCC from RTR (81-91%). 118, 125 An earlier, uncontrolled in situ hybridization (ISH) study showed HPV detection in 50% of SCC from RTRs. 126 A biopsybased study examining normal skin in OTRs with and without history of NMSC did not find a significant difference in HPV positivity between the two groups, although the group without a history of NMSC was small. 94 Not all studies point toward an association between HPV and SCC in immunocompromised patients. Two studies found a similar HPV DNA load in SCCs, BCCs, and premalignant and benign lesions in OTRs. 124, 127 Some have shown a significant association only when the analysis combined BCCs and SCCs. 84 A small early study using reverse transcriptase (RT)-PCR failed to detect any HPV DNA in 28 nongenital SCCs from immunosuppressed RTRs. 128 This may have been technique dependent, because using more-sensitive primer sets, Southern blotting, or RT-PCR could have increased the positive yield. 128, 129 A more-recent study showed that a high percentage (75%) of OTR SCCs were positive for HPV when screened using PCR; when examining transcriptional activity and DNA localization according to RNA and DNA, ISH positivity was 38% and 36%, respectively. 130 The authors feel that the detection of transcripts in keratinocytes suggests that HPV has an active, rather than passive, presence in these lesions. The same authors found low transcriptional activity in warts and suggested that the ISH technique used may lack sensitivity and that the low levels in SCC may therefore be an underestimate. 130 Although PCR HPV positivity may have been higher, the authors claim that ISH may be more biologically relevant (infection vs carriage or contamination).
A newer method using transcriptome sequencing of HPV in SCCs from RTRs and immunocompetent patients showed an absence of HPV gene expression (see above). 106 A study analyzing lesions from OTRs demonstrated low viral DNA load (for HPV 8, 9, 15) in SCCs and transcriptional activity (at low levels) of E6/7 (for HPV 5, 8, 9, 15, 20) in only one of seven SCCs. 131 Analysis of serial dilutions of HPV DNA from NMSCs revealed that HPV DNA could be detected only in undiluted DNA solutions, and based on the dilution of β-globin genes, it was estimated that HPV DNA was less than one viral genome per cell. 132 Studies of HPV seroprevalence in immunocompromised individuals with a history of SCC are scant. Longitudinal examination of different HPV-type seropositivity in this population and the correlation with new SCCs would be a complement to tissue studies.
Conclusion
Although UVR and immunosuppression predispose to SCC, the exact role of HPV in cutaneous oncogenesis remains to be elucidated. The evidence remains mixed for immunocompromised and immunocompetent populations. Challenges include the abundance of HPV types, the high rate of carriage in normal skin, the co-occurrence of multiple types, 133 immunologic cross-reactivity between types, and that possibility that HPV may be involved in initiation of oncogenesis but not in tumor maintenance.
To demonstrate that a pathogen causes cancer, we must have convincing epidemiologic evidence of association and a plausible biologic mechanism for oncogenesis. This has been demonstrated for the high-risk a-papillomaviruses and cervical cancer, but we have not yet satisfied these requirements to demonstrate that b-papillomaviruses cause cutaneous SCC. HPV appears to be ubiquitous in the skin, with greater prevalence in the setting of sun exposure or immunosuppression. The studies described here used multiple sampling and detection techniques, small sample sizes (with some exceptions), and detection restricted to specific HPV types.
Because of this heterogeneity in study design, a meta-analysis to power a true summary estimate of association might prove difficult.
More-recent studies have focused on the biologic mechanism for oncogenesis (reviewed by Arron 10 ). Although a complete review of this topic is beyond the scope of this review, evidence for low DNA viral loads and minimal gene expression in tumor tissue argue against HPV involvement in tumor maintenance. In vitro research has revealed that inflammatory gene expression by E6/E7 differs between a and b genera 134 and that b-papillomavirus E6/E7 proteins do not interfere in UVB-induced apoptosis. 135 Nevertheless, HPV may have a different, subtler involvement in cutaneous oncogenesis. The traditional notion that induction, proliferation, and the malignant phenotype must depend on the persistence of viral nucleic acid for an agent to be regarded causative may not apply in this setting. If HPV promotes cutaneous oncogenesis through the 'hit and run' phenomenon, acting as a cocarcinogen with other environmental factors such as UV radiation, 136 then high-risk patients may have to be followed temporally by tracking rates of HPV infection using various detection methods. Future SCC development in these patients will then have to be correlated with previous infection, because at the time of tumor development, some HPV types may have been cleared.
C U T A N E O U S S C C A N D H P V
The establishment of HPV involvement in SCC formation will have important implications for screening and prognosis. HPV may be involved in only a subset of SCCs or in high-risk populations. Detection of specific HPV types in cutaneous SCC may indicate a better prognosis, as is the case for head and neck SCC. 137 Conversely, it may carry a worse prognosis. In either case, clarifying the nature of this association, if any, would help tailor treatment. If HPV infection is associated with SCC in certain highrisk individuals, early vaccination against certain types may decrease future disease burden. This would be particularly relevant to the OTR population. Clarification of any viral mechanism in cutaneous SCC development would lead to enhanced treatment options and a reduction of the significant healthcare costs associated with this cancer.
